Calcifediol Market - Forecasts from 2022 to 2027
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 120 Pages
The calcifediol market is evaluated at US$1,204.233 million for the year 2020 and is projected to grow at a CAGR of 9.27% to reach a market size of US$2,239.841 million by the year 2027.
Calcifediol monohydrate (25-Hydroxyvitamin D3) is a vitamin D3 analogue created by hydroxylation of vitamin D3 (cholecalciferol) using the enzyme cholecalciferol 25-hydroxylase. Increasing expenditures on advanced pharmaceutical ingredients (API) manufacturing in emerging economies such as China and India is expected to keep the calcifediol monohydrate market growing. Furthermore, the global prevalence of chronic kidney disease (CKD) is increasing as a result of changing dietary patterns and a fast-paced work environment, which is boosting the demand for calcifediol monohydrate-based medications. According to the National Centre for Chronic Disease Prevention and Health Promotion (USA), chronic kidney disease affects about 15% of the population in the United States (CKD).
Additionally, the higher incidence of rickets and brittle bones is predicted to boost this industry's growth. According to the Centers for Disease Control and Prevention, rickets affects 5 out of every 1,000,000 children aged 6 months to 5 years. Also, companies are investing heavily in research and development. Because of the advantageous legislation regulating the manufacture and sale of vitamin D analogues and vitamin D3 APIs, leading manufacturers are locating their manufacturing facilities in Europe.
On the other hand, due to the high concentration and purity of vitamin D, the manufacture of this chemical necessitates the use of technologically advanced machinery and high monetary backup, along with factors affecting regulation and standardisation, which stifle industry growth to some extent.
Animal feed, pharmaceuticals, and others are the three application segments that make up the global calcifediol monohydrate market. The usage of calcifediol monohydrate in personal grooming and nutraceutical applications is covered under the other application areas. Broilers, cattle, breeders, and swine are projected to employ calcifediol monohydrate as an important source for calcium and phosphorus absorption in the body and calcium mobilization in bones in the animal sector. Additionally, it aids in the improvement of immune cells. Because of its widespread use in health supplements, injectables, and capsules, the pharmaceuticals segment is also expected to develop at a high CAGR During the forecast period.
The largest market, Asia Pacific, accounts for a considerable portion of the global calcifediol monohydrate market. Vitamin D deficiency is widespread throughout Asia Pacific, particularly in South - East Asia. Rickets is a disease induced by a deficiency of vitamin D that is particularly frequent in China. Furthermore, increasing income levels and significant consumer demand for nutritious and healthy products are anticipated to provide promising prospects for the expansion and development of the region's functional food and beverage products, resulting in increased consumption of vitamin-infused products and, as a result, market growth. Animal feed accounted for a majority of the calcifediol monohydrate generated in the region. The demand for animal feed is predicted to rise as the region's livestock production grows. Moreover, Europe is the second-largest user of calcifediol monohydrate after the United States. Because of the increased prevalence of kidney illnesses, the region is likely to grow rapidly.
The COVID-19 outbreak caused a substantially positive effect on the calcifediol market. Increasing evidence suggests that vitamin D plays a preventive role in lowering the risk and severity of respiratory tract infections (RTIs), particularly in the context of influenza and COVID-19. Major clinical findings demonstrate that vitamin D insufficiency has a role in the SARS-CoV-2 acute respiratory distress syndrome (ARDS) and that case fatality rates rise with age and SARS-CoV-2 serum concentrations. A multi-centre observational analysis of 537 COVID-19 patients found that those who received calcifediol had a lower mortality rate during the first 30 days of hospitalisation than those who did not. As a result, the calcifediol market had a significant role to play amid the COVID-19 pandemic.
DSM (Netherlands) and Zhejiang Xinhecheng Co Ltd. (China) inked a contract for the sale and purchase of cholesterol in January 2019. Vitamin D3 is made from cholesterol. This deal assisted the organisation in increasing its total capacity and Vitamin D productivity.
Fermenta Biotech Limited (India) signed a 99-year lease deal with the Gujarat Industrial Development Corporation (GIDC) authority in Ankleshwar, Sayakha in January 2019 to acquire a 40,000-square-meter plot of land for future expansion.
Middle East and Africa